TESARO Inc

Type: Company
Name: TESARO Inc
Nationality: United States
Web Address: http://tesarobio.com/
First reported Aug 23 2014 - Updated Aug 23 2014 - 1 reports

Business Digest for Aug. 23, 2014

Follow Daily News Business Editor Bob Tremblay on Twitter @Bob Tremblay_MW. Body Uniqlo to open stores in Natick, Chestnut Hill Uniqlo, the Japanese casual wear designer, manufacturer and retailer, opens its first two permanent stores in Massachusetts ... [Published MetroWest Daily News - Aug 23 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

Tekmira Up On Positive Ebola-Related Drug Study; Philips Receives FDA 510(k) Clearance For TAVI

Below is a look at some of the headlines for companies that made news in the healthcare sector on August 21, 2014.Tekmira Pharmaceuticals (NASDAQ: TKMR) shares gained more than four percent after it was reported that one of its drugs showed promising ... [Published BioMedReports - Aug 22 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

TESARO : Paradigm Announces Molecular Profiling Collaboration with TESARO

Paradigm will use its advanced molecular capabilities to characterize patient tissue samples from clinical trials to better predict which patients may be sensitive or resistant to TESARO's TSR-011.This may lead to more successful clinical trial outcomes ... [Published 4 Traders - Aug 21 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 4 reports

TESARO Announces Participation at Several Upcoming Investor Conferences

WALTHAM, Mass., Aug. 21, 2014 (GLOBE NEWSWIRE) -- TESAROAbout TESAROTESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. ... [Published BusinessWeek - Aug 21 2014]
First reported Aug 20 2014 - Updated Aug 21 2014 - 3 reports

Paradigm collaborates with TESARO on molecular profiling

Paradigm today announced a collaboration with TESARO. ... [Published PBR - News - Aug 21 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

TESARO (TSRO) Slips on Wider-than-Expected Q2 Loss

TESARO, Inc. ’s ( TSRO ) shares continued to decline after the company reported a wider-than-expected loss for the second quarter of 2014. Shares, which declined 5.2% immediately after the release of second quarter results, slipped a further 1.5% in the ... [Published Yahoo! Finance - Jul 30 2014]
First reported Jul 27 2014 - Updated Jul 27 2014 - 1 reports

Tesaro Q2 loss widens

Tesaro (TSRO), an oncology-focused biopharmaceutical company, saw its loss widen to $37.05 million or $1.03 a share for the quarter ended Jun. 30, 2014. In the last year period, the company posted a loss of $21.56 million or $0.67 a share. Analysts on ... [Published MyIris - Jul 27 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 5 reports

Tesaro, Inc. Announces Second-Quarter 2014 Operating Results

TESARO reported a net loss of $37.1 million, or $1.03 per share, for the second quarter of 2014, compared to a net loss of $21.6 million, or $0.67 per share, for the second quarter of 2013.Research and development expenses increased to $30.6 million for ... [Published BioSpace - Jul 25 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

TESARO Q2 Loss Widens

TESARO Inc. (TSRO: Quote) posted second-quarter net loss of $37.1 million or $1.03 per share, wider than $21.6 million or $0.67 per share in the comparable quarter last year.On average, six analysts polled by Thomson Reuters expected the company to report ... [Published RTTNews.com - Jul 25 2014]
Entities: TESARO Inc
First reported Jul 23 2014 - Updated Jul 24 2014 - 2 reports

Sofinnova Raises $500 Million Biotech Venture Fund

MENLO PARK, Calif.Sofinnova focuses exclusively on helping entrepreneurs build successful biotechnology companies. Consistent with recent funds, SVP IX will provide capital primarily to companies with promising later stage clinical programs, along with ... [Published Bio-Medicine - Jul 23 2014]
First reported May 12 2014 - Updated May 13 2014 - 2 reports

Rolapitant eases nausea in cancer patients Tesaro soars

| SCRIPTesaro's stock closed 21% higher on 12 May after the company said rolapitant met all primary and secondary endpoints in a Phase III clinical trial for cancer patients with chemotherapy-induced nausea and vomiting (CINV) with a potentially diff ... [Published BioPortfolio - May 13 2014]
First reported May 12 2014 - Updated May 13 2014 - 2 reports

Why Tesaro (TSRO) Stock Is Surging Today

NEW YORK (TheStreet) -- Tesaro  surged Monday after the biopharmaceutical company announced positive top-line results from the third and final Phase 3 trial of rolapitant, an investigational neurokinin-1, or NK-1, receptor antagonist in development for ... [Published The Street Latest - May 12 2014]

Quotes

...those patients who might have once been considered too high-risk for heart surgery," said Gene Saragnese, CEO, Imaging Systems, Philips Healthcare. "Treating cardiac conditions requires intense precision and our TAVI planning application delivers a solution for aortic device placement to help improve patient care."
Robert J Penny MD, PhD, CEO of Paradigm noted "Paradigm is utilizing decades of know how in successfully working with the pharmaceutical and diagnostic industry and merging those with our unique academic research abilities to craft personalized interrogations for clinical trial selection and provide accelerated translational treatment decisions in patient care."
...clinical trials conducted with nutritional vitamin D in CKD patients and this study concluded, this paper concluded, and I'm quoting the article, "most of the studies have shown either no or minimal to inadequate changes in PTH levels"
"The rolapitant NDA remains on track for submission to the US FDA in approximately six weeks, and pre-launch commercial activities are well underway. We are also pleased with the pace of enrollment in our Phase 3 niraparib NOVA trial for patients with ovarian cancer, and we expect the non-germline BRCA cohort to be fully enrolled at the end of this year."

More Content

All (76) | News (43) | Reports (0) | Blogs (15) | Audio/Video (0) | Fact Sheets (0) | Press Releases (18)
sort by: Date | Relevance
Business Digest for Aug. 23, 2014 [Published MetroWest Daily News - Aug 23 2014]
Competition And Momentum Weighing On Clovis Onc... [Published Seeking Alpha - Aug 23 2014]
Tekmira Up On Positive Ebola-Related Drug Study... [Published BioMedReports - Aug 22 2014]
TESARO : Paradigm Announces Molecular Profiling... [Published 4 Traders - Aug 21 2014]
TESARO Announces Participation at Several Upcom... [Published GlobeNewswire: Acquisitions News - Aug 21 2014]
TESARO Announces Participation at Several Upcom... [Published BusinessWeek - Aug 21 2014]
TESARO Announces Participation at Several Upcom... [Published EMoneyDaily - Aug 21 2014]
TESARO Announces Participation at Several Upcom... [Published Minyanville - Aug 21 2014]
TESARO Announces Participation at Several Upcom... [Published The CW44 Tampa Bay - Aug 21 2014]
Paradigm collaborates with TESARO on molecular ... [Published PBR - News - Aug 21 2014]
Paradigm Announces Molecular Profiling Collabor... [Published KSWO - Aug 20 2014]
Paradigm Announces Molecular Profiling Collabor... [Published PR Newswire: Health - Aug 20 2014]
Healthcare & Biotech Hedge Funds see asset surg... [Published Hedge Tracker - Aug 14 2014]
OPKO Health's (OPK) CEO Phillip Frost on Q2 201... [Published Seeking Alpha - Aug 12 2014]
OPKO Announces Second Quarter Operating and Fin... [Published Industrial Info Financials - Aug 11 2014]
TESARO (TSRO) Slips on Wider-than-Expected Q2 Loss [Published Yahoo! Finance - Jul 30 2014]
Tesaro Q2 loss widens [Published MyIris - Jul 27 2014]
Business Digest for July 26, 2014 [Published MetroWest Daily News - Jul 26 2014]
TESARO Trading Down 5.9% Following Weak Earning... [Published American Banking News - Jul 25 2014]
Friday's ETF Movers: GDXJ, XBI [Published Forbes.com - Jul 25 2014]
Tesaro, Inc. Announces Second-Quarter 2014 Oper... [Published BioSpace - Jul 25 2014]
Frontrunning: July 25 [Published Zero Hedge - Jul 25 2014]
TESARO's' (TSRO) CEO Lonnie Moulder on Q2 2014 ... [Published Seeking Alpha - Jul 25 2014]
TESARO Q2 Loss Widens [Published RTTNews.com - Jul 25 2014]
Keryx Announces Zerenex LT Phase 3 Results; Esp... [Published BioMedReports - Jul 25 2014]
TESARO Announces Second-Quarter 2014 Operating ... [Published GlobeNewswire: Advertising News - Jul 24 2014]
TESARO Announces Second-Quarter 2014 Operating ... [Published EMoneyDaily - Jul 24 2014]
TESARO Appoints Mary Lynne Hedley, Ph.D., as Ch... [Published EMoneyDaily - Jul 24 2014]
TESARO Announces Second-Quarter 2014 Operating ... [Published Stock Nod - Jul 24 2014]
TESARO Announces Second-Quarter 2014 Operating ... [Published Fat Pitch Financials - Jul 24 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Paradigm collaborates with TESARO on molecular ... [Published PBR - News - Aug 21 2014]
Paradigm today announced a collaboration with TESARO. ...
Paradigm Announces Molecular Profiling Collabor... [Published PR Newswire: Health - Aug 20 2014]
ANN ARBOR, Mich. and PHOENIX, Aug. 20, 2014 /PRNewswire-USNewswire/ -- Paradigm, a non-profit corporation established to bring cutting-edge next-generation sequencing and proteomic diagnostics and biomarker driven clinical trials to cancer patients, ...
Frontrunning: July 25 [Published Zero Hedge - Jul 25 2014]
Argentine holdout NML says government "choosing" to default ( Reuters ) Crunch time for Gaza truce talks as death toll passes 800 ( Reuters ) Don’t Tell Anybody About This Story on HFT Power Jump Trading ( BBG ) U.S. Accuses Russia of Shelling Eastern ...
Boston CEO Conference to Feature CEOs of Aegeri... [Published Business Wire Health News - May 20 2014]
BOSTON--(BUSINESS WIRE)--More than 200 leading CEOs from the biotechnology community will gather at the 2014 Boston CEO Conference June 4th and 5th at the Four Seasons Hotel in Boston. Past award winners Henri Termeer, Josh Boger, Deborah Dunsire and ...
Clinical Trial Updates, Leadership Appointments... [Published PR Newswire: Financial Services - May 15 2014]
NEW YORK, May 15, 2014 /PRNewswire/ --Today, Analysts Review released its analysts' notes regarding Tesaro, Inc. (NASDAQ: TSRO), Novavax, Inc. (NASDAQ: NVAX), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Insmed Incorporated (NASDAQ: INSM) and Durata Therapeutics, ...
1 2 3

Press Releases

sort by: Date | Relevance
TESARO Announces Participation at Several Upcom... [Published GlobeNewswire: Acquisitions News - Aug 21 2014]
TESARO Announces Second-Quarter 2014 Operating ... [Published GlobeNewswire: Advertising News - Jul 24 2014]
TESARO to Announce Second-Quarter 2014 Financia... [Published GlobeNewswire: Advertising News - Jul 10 2014]
Market Expansion, Merger Agreements, Management... [Published Financial Services - Jul 02 2014]
TESARO Summarizes Rolapitant Data Presented at ... [Published GlobeNewswire: Acquisitions News - Jun 27 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.